Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
Novel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2013/651902 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563230206066688 |
|---|---|
| author | Shigeki Ito Tatsuo Oyake Kazunori Murai Yoji Ishida |
| author_facet | Shigeki Ito Tatsuo Oyake Kazunori Murai Yoji Ishida |
| author_sort | Shigeki Ito |
| collection | DOAJ |
| description | Novel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatment strategy, including increase in the dosage of current agents and addition of other agents, may be considered for these patients. We here describe 2 myeloma patients with acquired resistance to bortezomib or lenalidomide, in whom add-on therapy with low-dose cyclophosphamide was effective and tolerable. These cases suggest that add-on therapy with cyclophosphamide is one of the treatment options to overcome resistance to novel agents in patients with multiple myeloma. A larger prospective study is needed to clarify the efficacy and safety of this strategy for novel agent-resistant multiple myeloma. |
| format | Article |
| id | doaj-art-921fc895c81a4baaac3ed13c34c780ad |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-921fc895c81a4baaac3ed13c34c780ad2025-02-03T01:20:39ZengWileyCase Reports in Hematology2090-65602090-65792013-01-01201310.1155/2013/651902651902Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or LenalidomideShigeki Ito0Tatsuo Oyake1Kazunori Murai2Yoji Ishida3Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, JapanHematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, JapanHematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, JapanHematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, JapanNovel agents such as thalidomide, lenalidomide, and bortezomib have been shown to possess potent activity against multiple myeloma. However, the treatment strategy for patients who acquired resistance to these agents has not been established. In addition to switching drug classes, intensified treatment strategy, including increase in the dosage of current agents and addition of other agents, may be considered for these patients. We here describe 2 myeloma patients with acquired resistance to bortezomib or lenalidomide, in whom add-on therapy with low-dose cyclophosphamide was effective and tolerable. These cases suggest that add-on therapy with cyclophosphamide is one of the treatment options to overcome resistance to novel agents in patients with multiple myeloma. A larger prospective study is needed to clarify the efficacy and safety of this strategy for novel agent-resistant multiple myeloma.http://dx.doi.org/10.1155/2013/651902 |
| spellingShingle | Shigeki Ito Tatsuo Oyake Kazunori Murai Yoji Ishida Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide Case Reports in Hematology |
| title | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide |
| title_full | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide |
| title_fullStr | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide |
| title_full_unstemmed | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide |
| title_short | Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide |
| title_sort | successful use of cyclophosphamide as an add on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide |
| url | http://dx.doi.org/10.1155/2013/651902 |
| work_keys_str_mv | AT shigekiito successfuluseofcyclophosphamideasanaddontherapyformultiplemyelomapatientswithacquiredresistancetobortezomiborlenalidomide AT tatsuooyake successfuluseofcyclophosphamideasanaddontherapyformultiplemyelomapatientswithacquiredresistancetobortezomiborlenalidomide AT kazunorimurai successfuluseofcyclophosphamideasanaddontherapyformultiplemyelomapatientswithacquiredresistancetobortezomiborlenalidomide AT yojiishida successfuluseofcyclophosphamideasanaddontherapyformultiplemyelomapatientswithacquiredresistancetobortezomiborlenalidomide |